NEW YORK (GenomeWeb News) — Underwriters taking part in Rosetta Genomics’ initial public offering last month bought 562,000 additional shares as part of an over-allotment.
.
The over-allotment makes the total IPO’s net value $26.2 million on 4.3 million shares sold, after the initial sale of 3.75 million shares at $7 a share.
 
Rosetta’s stock was down 2.4 percent at $8.15 in early-afternoon trading today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

The Economist writes that an increasing number of scientific journals don't do peer review.

In Science this week: genetic overlap among many psychiatric disorders, and more.